OTC Markets OTCPK - Delayed Quote USD

MYND Life Sciences Inc. (MYNDF)

0.0100
0.0000
(0.00%)
At close: May 16 at 4:00:00 PM EDT
Loading Chart for MYNDF
  • Previous Close 0.0000
  • Open 0.0450
  • Bid 0.0130 x --
  • Ask 0.1215 x --
  • Day's Range 0.0450 - 0.0675
  • 52 Week Range 0.0100 - 0.0723
  • Volume 7,920
  • Avg. Volume 521
  • Market Cap (intraday) 2.398M
  • Beta (5Y Monthly) 1.37
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.

www.myndsciences.com

--

Full Time Employees

October 31

Fiscal Year Ends

Recent News: MYNDF

View More

Performance Overview: MYNDF

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

MYNDF
82.43%
S&P/TSX Composite index (^GSPTSE)
5.49%

1-Year Return

MYNDF
59.84%
S&P/TSX Composite index (^GSPTSE)
16.47%

3-Year Return

MYNDF
86.28%
S&P/TSX Composite index (^GSPTSE)
28.53%

5-Year Return

MYNDF
98.64%
S&P/TSX Composite index (^GSPTSE)
77.42%

Compare To: MYNDF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MYNDF

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    2.39M

  • Enterprise Value

    4.54M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    652.75k

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    6.35M

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -151.46%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1

  • Net Income Avi to Common (ttm)

    -542.57k

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    497

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -658.04k

Research Analysis: MYNDF

View More

Company Insights: MYNDF

Research Reports: MYNDF

View More

People Also Watch